Literature DB >> 20541248

A single nucleotide polymorphism in the CCR3 gene ablates receptor export to the plasma membrane.

Emma L Wise1, Kandace T Bonner, Timothy J Williams, James E Pease.   

Abstract

BACKGROUND: The chemokine receptor CCR3 orchestrates the migration of eosinophils, basophils, T(H)2 lymphocytes, and mast cells during the allergic response, with CCR3 blockade a potential means of therapeutic intervention. Non-synonymous single nucleotide polymorphisms (SNPs) within the ccr3 gene have previously been described, with little information regarding their effects on CCR3 function.
OBJECTIVE: To characterize the effects of nonsynonymous SNPs within the ccr3 gene.
METHODS: Site-directed mutagenesis was used to generate N-terminally tagged mutant CCR3 constructs corresponding to reported SNPs. Cell transfectants expressing either wild-type or mutant CCR3 were studied by flow cytometry, Western blotting, and confocal microscopy and examined for their ability to migrate to the CC chemokine ligand CCL11/eotaxin.
RESULTS: An L324P mutant CCR3 protein corresponding to the previously identified T971C SNP was not expressed at the cell surface, and cells remained unresponsive to CCL11 in chemotaxis assays. Confocal microscopy confirmed that L324P-CCR3 had a predominantly intracellular distribution compared with wild-type CCR3. A L324A variant of CCR3 had an identical phenotype to the L324P mutant, suggesting that L324 per se is critical for successful trafficking of nascent CCR3 to the cell membrane. The processes involved appear to be specific for CCR3, because an identical mutation in the homologous receptor CCR1 had minor effects.
CONCLUSION: Trafficking to the cell surface of nascent CCR3 is critically dependent on a C-terminal leucine residue, suggestive of specific mechanisms for CCR3 export. Manipulation of these mechanisms may suggest novel means of antagonizing CCR3 function in the treatment of allergy. Copyright 2010 American Academy of Allergy, Asthma & Immunology. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20541248     DOI: 10.1016/j.jaci.2010.04.015

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  4 in total

Review 1.  Pharmacoperones as Novel Therapeutics for Diverse Protein Conformational Diseases.

Authors:  Ya-Xiong Tao; P Michael Conn
Journal:  Physiol Rev       Date:  2018-04-01       Impact factor: 37.312

2.  Novel peptide nanoparticle-biased antagonist of CCR3 blocks eosinophil recruitment and airway hyperresponsiveness.

Authors:  Milica Grozdanovic; Kimberly G Laffey; Hazem Abdelkarim; Ben Hitchinson; Anantha Harijith; Hyung-Geon Moon; Gye Young Park; Lee K Rousslang; Joanne C Masterson; Glenn T Furuta; Nadya I Tarasova; Vadim Gaponenko; Steven J Ackerman
Journal:  J Allergy Clin Immunol       Date:  2018-05-17       Impact factor: 10.793

3.  Common α2A and α2C adrenergic receptor polymorphisms do not affect plasma membrane trafficking.

Authors:  Carl M Hurt; Matt W Sorensen; Timothy Angelotti
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2014-03-19       Impact factor: 3.000

Review 4.  Eosinophils: changing perspectives in health and disease.

Authors:  Helene F Rosenberg; Kimberly D Dyer; Paul S Foster
Journal:  Nat Rev Immunol       Date:  2012-11-16       Impact factor: 53.106

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.